The Current issue of “The view from here” is concerned with We are family

The topic of this month’s newsletter from Drug Discovery Today is “We are family”.

Drug Discovery Today isn’t just a single publication; over the years it has had some significant offspring. In the early 2000s, there were two other titles – Drug Discovery Today – Targets and Drug Discovery Today - Biosilico. These titles were intended to provide a service and safe haven for review articles on proteomics, genomics and bio or chemoinformatics. Over the years, it became prudent to incorporate these titles into the main journal and you may still see that the original colour palette from the original titles was retained in these articles. Around that time, other journals were launched and in this newsletter, we will be featuring some of the most impactful articles published recently. So please excuse the lack of general theme in this month’s offering.

The first article featured in this “best of” newsletter is from Drug Discovery Today: Disease Models in the issue “Animal Models for Exploring the Microbiome” by  Simon Spichak, Katherine E. Guzzetta, Olivia F. O’Leary, Gerard Clarke, Timothy G. Dinan and John F.Cryan, entitled: “Without a bug’s life: Germ-free rodents to interrogate microbiota-gut-neuroimmune interactions”.  This is an interesting approach in that as we become more aware of how the gut microbiome can affect the effects of drugs and physiological processes. 
The second article in this newsletter (and from the same issue at the previous article) is entitled: “Model systems for the study of how symbiotic associations between animals and extracellular bacterial partners are established and maintained”. By Eric J. Koch and Margaret McFall-Ngai of Kewalo Marine Laboratory, University of Hawai?i at Manoa, Hawaii  USA. This article highlights the current state of play with respect to models for the study of host-microbe association. Such models may be of great importance in how drug development may play a role in the development and maintenance of healthy interplay between animals and microbes. 
Finally, I have included an article from Drug Discovery Today: Technologies entitled “Protein degradation for drug discovery” by Alessio Ciulli and William Farnaby from the University of Dundee. This article highlights and outlines all of the articles contained within this themed issue. The articles in this issue are of great interest and I’ve listed them here for your information:
R. Chopra, A. Sadok, I. Collins A critical evaluation of the approaches to targeted protein degradation for drug discovery 10.1016/j.ddtec.2019.02.002
M. Pettersson, C.M. Crews PROteolysis TArgeting Chimeras (PROTACs) — Past, present and future 10.1016/j.ddtec.2019.01.002
P.P. Chamberlain, B.E. Cathers Cereblon modulators: Low molecular weight inducers of protein degradation 10.1016/j.ddtec.2019.02.004
M. Naito, N. Ohoka, N. Shibata SNIPERs—Hijacking IAP activity to induce protein degradation 10.1016/j.ddtec.2018.12.002
Y. Zhang, C. Loh, J. Chen, N. Mainolfi Targeted protein degradation mechanisms
D.L. Daniels, K.M. Riching, M. Urh Monitoring and deciphering protein degradation pathways inside cells 10.1016/j.ddtec.2018.12.001
P. Grandi, M. Bantscheff Advanced proteomics approaches to unravel protein homeostasis 10.1016/j.ddtec.2019.02.001
A. Yesbolatova, Y. Tominari, M.T. Kanemaki Ligand-induced genetic degradation as a tool for target validation 10.1016/j.ddtec.2018.11.001
Steve Carney was born in Liverpool, England and studied Biochemistry at Liverpool University, obtaining a BSc.(Hons) and then read for a PhD on the Biochemistry and Pathology of Connective Tissue Diseases in Manchester University, in the Departments of Medical Biochemistry and Histopathology. On completion of his PhD he moved to the Kennedy Institute of Rheumatology, London, where he worked with Professor Helen Muir FRS and Professor Tim Hardingham, on the biochemistry of experimental Osteoarthritis. He joined Eli Lilly and Co. and held a number of positions in Biology R&D, initially in the Connective Tissue Department, but latterly in the Neuroscience Department. He left Lilly to take up his present position as Managing Editor, Drug Discovery Today, at Elsevier. Currently, he also holds an honorary lectureship in Drug Discovery at the University of Surrey, UK. He has authored over 50 articles in peer-reviewed journals, written several book chapters and has held a number of patents. 

Share this article

More services


This article is featured in:
The View From Here


Comment on this article

You must be registered and logged in to leave a comment about this article.